CDI
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
MRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026
MRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026 MRSA, MSSA, Gram-negative bacteraemia infections by organisation and location of onset, and Clostridioides difficile infections (CDI) by organisation and prior trust exposure. Documents Details For data before January 2025 to 2026, see our previous reports. These official statistics were independently reviewed by the Office for Statistics Regulation in May 2022.
A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
Abstract Nuclear receptors are central regulators of metabolism1, yet therapeutic strategies that enforce continuous receptor activation frequently lead to reduced efficacy and unacceptable toxicity. Here we report a first-principles drug design strategy that aligns pharmacokinetics with physiological signalling cycles. We developed linafexor, a potent non-bile-acid agonist of the farnesoid X receptor (FXR)2; it is engineered for rapid systemic clearance, which enables pulsatile receptor...